Candel Therapeutics Eyes 2026 Prostate Cancer Filing as Lung Study Ramps Up

NDA FilingPositive

AI Analysis

Summary

Candel Therapeutics is targeting a prostate cancer regulatory filing in 2026 while advancing its lung cancer study program. The company is progressing its pipeline with plans to submit for approval in the near-term future.

Importance:5/10

Sentiment:

0.30

clinical developmentprostate cancerlung cancerregulatory filing

Related Companies

$CADL

Read the original article

Published by yahoo_finance on August 12, 2026 5:04 PM

Read Original